Pfizer Stock Fell 2.8%. Did Investors Misunderstand the Revenue Guidance?

4 months ago 104
PR Distribution

This copy is for your personal, non-commercial use only. To order presentation-ready copies for distribution to your colleagues, clients or customers visit

Updated Feb. 8, 2022 4:16 pm ET / Original Feb. 8, 2022 4:15 pm ET

  • Order Reprints
  • Print Article

Pfizer shares dropped sharply on Tuesday after the company’s 2022 sales guidance appeared to fall short of expectations.

The guidance that Pfizer (ticker: PFE) presented, however, doesn’t take into account future sales of Pfizer’s Covid-19 vaccine and antiviral, but only sales already made. The number will likely climb upward as the year progresses, suggesting that the selloff on Tuesday may have been based on a misunderstanding.


Read Entire Article